Icon PLC header image

Icon PLC

ICLR

Equity

ISIN IE0005711209 / Valor 1017575

NASDAQ (2026-05-01)
USD 112.85-4.63%

Icon PLC
UMushroom community rating:

star star star star star
2.00 1 votes No rating yet
NegativeNeutralPositive

About company

ICON plc is a leading global provider of outsourced drug and medical device development and commercialization services, catering to pharmaceutical, biotechnology, and medical device companies as well as government and public health organizations. The company specializes in managing the entire product lifecycle, including the planning, execution, and analysis of Phase I-IV clinical trials, which range from small single-site studies to large, multinational projects and advancements in cell and gene therapy. ICON also offers Functional Service Provision (FSP), delivering essential support services in areas such as finance, IT, human resources, sales, quality assurance, facilities, administration, legal, and procurement. With over 13,000 employees and more than 90 global partnerships, ICON integrates its Strategic Solutions teams within clients' operations to enhance efficiency and accelerate the market entry of new therapeutics and devices. Additionally, ICON is committed to developing talent through various early career programs, fostering a culture of continuous learning and professional growth.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-22.3%1Y
-42.3%3Y
-48.0%5Y

Performance

74.3%1Y
51.3%3Y
45.8%5Y

Volatility

Market cap

8617 M

Market cap (USD)

Daily traded volume (Shares)

1,000,929

Daily traded volume (Shares)

1 day high/low

211.185 / 207.1

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

2.00

1 votes
Performance:
starstarstarstarstar
2.00
Innovation:
starstarstarstarstar
1.00
Society:
starstarstarstarstar
1.00
Nature:
starstarstarstarstar
1.00
Aleenah Moghal
United Kingdom, 17 Feb 2026
star star star star star
Icon PLC faces significant uncertainty ue to an ongoing investigation into potential revenue overstatements for 2023–2025. this has led to significant price drops observed due to allegations that ICON plc may have issued materially misleading business information to the investing public.

EQUITIES OF THE SAME SECTOR

Amphastar Pharmaceuticals Inc
Amphastar Pharmaceuticals Inc Amphastar Pharmaceuticals Inc Valor: 24511852
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.36%USD 21.88
Schrodinger Inc
Schrodinger Inc Schrodinger Inc Valor: 51947209
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.60%USD 12.39
International Flavors & Fragrances Inc
International Flavors & Fragrances Inc International Flavors & Fragrances Inc Valor: 941876
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.87%USD 70.81
MannKind Corp
MannKind Corp MannKind Corp Valor: 35935511
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.35%USD 2.84
Outset Medical Inc
Outset Medical Inc Outset Medical Inc Valor: 56717137
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.11%USD 4.36
BridgeBio Pharma Inc
BridgeBio Pharma Inc BridgeBio Pharma Inc Valor: 48204826
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.59%USD 68.56
Protagonist Therapeutics Inc
Protagonist Therapeutics Inc Protagonist Therapeutics Inc Valor: 33278818
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.61%USD 98.37
Allogene Therapeutics Inc
Allogene Therapeutics Inc Allogene Therapeutics Inc Valor: 43756548
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.94%USD 2.15
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-24.91%USD 16.11
Glaukos Corp
Glaukos Corp Glaukos Corp Valor: 28262610
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.40%USD 140.22